|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/497 | (2006.01) |
| A61K 31/497 | (2013.01) | ||
| A61K 31/5377 | (2006.01) | ||
| A61K 31/5377 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 37/00 | (2018.01) |
| (11) | Patento numeris | 4069237 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 20829249.0 |
| Europos patento paraiškos padavimo data | 2020-12-03 | |
| (97) | Europos patento paraiškos paskelbimo data | 2022-10-12 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2025-04-09 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2020/063176 |
| Data | 2020-12-03 |
| (87) | Numeris | WO 2021/113557 |
| Data | 2021-06-10 |
| (30) | Numeris | Data | Šalis |
| 201962943720 P | 2019-12-04 | US | |
| 202063010524 P | 2020-04-15 | US |
| (72) |
SANDS, Arthur T. , US
KELLY, Aileen , US
|
| (73) |
Nurix Therapeutics, Inc. ,
1700 Owens Street Suite 205, San Francisco, CA 94158,
US
|
| (54) | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY |
| BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY |